Valeo Pharma Stock Performance
| VPHIF Stock | USD 0.05 0.00 0.00% |
The entity has a beta of -0.56, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Valeo Pharma are expected to decrease at a much lower rate. During the bear market, Valeo Pharma is likely to outperform the market. Valeo Pharma right now has a risk of 0.0%. Please validate Valeo Pharma information ratio and kurtosis , to decide if Valeo Pharma will be following its existing price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Valeo Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable forward indicators, Valeo Pharma is not utilizing all of its potentials. The newest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 2 M |
Valeo |
Valeo Pharma Relative Risk vs. Return Landscape
If you would invest 4.69 in Valeo Pharma on August 30, 2024 and sell it today you would earn a total of 0.00 from holding Valeo Pharma or generate 0.0% return on investment over 90 days. Valeo Pharma is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Valeo, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Valeo Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Valeo Pharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Valeo Pharma, and traders can use it to determine the average amount a Valeo Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| VPHIF |
Based on monthly moving average Valeo Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Valeo Pharma by adding Valeo Pharma to a well-diversified portfolio.
Valeo Pharma Fundamentals Growth
Valeo Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Valeo Pharma, and Valeo Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Valeo Pink Sheet performance.
| Return On Equity | -16.0 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (0.93) % | |||
| Operating Margin | (0.61) % | |||
| Current Valuation | 57.28 M | |||
| Shares Outstanding | 82.19 M | |||
| Price To Book | 66.75 X | |||
| Price To Sales | 2.14 X | |||
| Revenue | 27.75 M | |||
| EBITDA | (19.04 M) | |||
| Cash And Equivalents | 27.72 M | |||
| Cash Per Share | 0.34 X | |||
| Total Debt | 59.53 M | |||
| Book Value Per Share | (0.22) X | |||
| Cash Flow From Operations | (28.5 M) | |||
| Earnings Per Share | (0.21) X | |||
| Total Asset | 58.27 M | |||
About Valeo Pharma Performance
By analyzing Valeo Pharma's fundamental ratios, stakeholders can gain valuable insights into Valeo Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Valeo Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Valeo Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. The company was incorporated in 2003 and is headquartered in Kirkland, Canada. Valeo Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 100 people.Things to note about Valeo Pharma performance evaluation
Checking the ongoing alerts about Valeo Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Valeo Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Valeo Pharma generated a negative expected return over the last 90 days | |
| Valeo Pharma has some characteristics of a very speculative penny stock | |
| Valeo Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 27.75 M. Net Loss for the year was (25.75 M) with profit before overhead, payroll, taxes, and interest of 8.52 M. | |
| Valeo Pharma has accumulated about 27.72 M in cash with (28.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 48.0% of the company outstanding shares are owned by insiders |
- Analyzing Valeo Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Valeo Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Valeo Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Valeo Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Valeo Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Valeo Pharma's pink sheet. These opinions can provide insight into Valeo Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Valeo Pink Sheet analysis
When running Valeo Pharma's price analysis, check to measure Valeo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Valeo Pharma is operating at the current time. Most of Valeo Pharma's value examination focuses on studying past and present price action to predict the probability of Valeo Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Valeo Pharma's price. Additionally, you may evaluate how the addition of Valeo Pharma to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |